Potential anti-tumor effects of FTY720 associated with PP2A activation: a brief review
作者： Ion Cristóbal , Juan Madoz-Gúrpide , Rebeca Manso , Paula González-Alonso , Federico Rojo
DOI: 10.1185/03007995.2016.1162774
关键词:
摘要: FTY720 (Fingolimod, Gilenya (†) ) is an FDA-approved immunosuppressant currently used in the treatment of multiple sclerosis. However, a large number studies over last few years have shown that shows potent antitumor properties suggest its potential usefulness as novel anticancer agent. Interestingly, restoration protein phosphatase 2A (PP2A) activity mediated by could play key role effects. Taking into account PP2A inactivation common event determines poor outcome several tumor types, serve alternative therapeutic strategy for cancer patients with such alterations.
sci-hub.se 参考文章(88)
K-F Chen, C-Y Liu, Y-C Lin, H-C Yu, T-H Liu, D-R Hou, P-J Chen, A-L Cheng, CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene. ,vol. 29, pp. 6257- 6266 ,(2010) , 10.1038/ONC.2010.357
Masato Tamaki, Takanori Goi, Yasuo Hirono, Kanji Katayama, Akio Yamaguchi, PPP2R1B gene alterations inhibit interaction of PP2A-Aβ and PP2A-C proteins in colorectal cancers Oncology Reports. ,vol. 11, pp. 655- 659 ,(2004) , 10.3892/OR.11.3.655
Francesca Zonta, Mario Angelo Pagano, Livio Trentin, Elena Tibaldi, Federica Frezzato, Valentina Trimarco, Monica Facco, Giuseppe Zagotto, Valeria Pavan, Giovanni Ribaudo, Luciana Bordin, Gianpietro Semenzato, Anna Maria Brunati, Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2A. Blood. ,vol. 125, pp. 3747- 3755 ,(2015) , 10.1182/BLOOD-2014-12-619155
Yan Yang, Qing Huang, Yanjun Lu, Xiaoqing Li, Shiang Huang, Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation. Journal of Cellular Biochemistry. ,vol. 113, pp. 1314- 1322 ,(2012) , 10.1002/JCB.24003
Liang Ma, Zhe-Sheng Wen, Zi Liu, Zheng Hu, Jun Ma, Xiao-Qin Chen, Yong-Qiang Liu, Jian-Xin Pu, Wei-Lie Xiao, Han-Dong Sun, Guang-Biao Zhou, Overexpression and Small Molecule-Triggered Downregulation of CIP2A in Lung Cancer PLOS ONE. ,vol. 6, ,(2011) , 10.1371/JOURNAL.PONE.0020159
M. Janghorban, A. S. Farrell, B. L. Allen-Petersen, C. Pelz, C. J. Daniel, J. Oddo, E. M. Langer, D. J. Christensen, R. C. Sears, Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer Proceedings of the National Academy of Sciences of the United States of America. ,vol. 111, pp. 9157- 9162 ,(2014) , 10.1073/PNAS.1317630111
M. Mehling, T. A. Johnson, J. Antel, L. Kappos, A. Bar-Or, Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis Neurology. ,vol. 76, ,(2011) , 10.1212/WNL.0B013E31820DB341
Masayuki Nagahashi, Nitai C. Hait, Michael Maceyka, Dorit Avni, Kazuaki Takabe, Sheldon Milstien, Sarah Spiegel, Sphingosine-1-phosphate in chronic intestinal inflammation and cancer Advances in Biological Regulation. ,vol. 54, pp. 112- 120 ,(2014) , 10.1016/J.JBIOR.2013.10.001
Ralf Ruediger, Huong T Pham, Gernot Walter, Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the Aα subunit gene Oncogene. ,vol. 20, pp. 10- 15 ,(2001) , 10.1038/SJ.ONC.1204059
Wei Qu, Wenjuan Li, Ling Wei, Ligang Xing, Xingwu Wang, Jinming Yu, CIP2A is overexpressed in esophageal squamous cell carcinoma. Medical Oncology. ,vol. 29, pp. 113- 118 ,(2012) , 10.1007/S12032-010-9768-9